Skip to main
CRIS
CRIS logo

Curis (CRIS) Stock Forecast & Price Target

Curis (CRIS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Curis Inc demonstrates a positive outlook due to its innovative approach targeting key mutations involved in leukemogenesis, specifically IRAK4 and FLT3, which enhances the therapeutic potential of its drug candidates. The company has provided strong preclinical data that shows a synergistic effect from dual blockade strategies, suggesting significant improvements in tumor reduction over traditional monotherapy approaches. Furthermore, the ongoing development of its comprehensive pipeline, which includes several promising products aimed at various cancer types, positions Curis favorably within the competitive biopharmaceutical landscape.

Bears say

Curis Inc. is facing a negative outlook primarily due to depressed forward multiples attributed to ongoing market volatility, which may hinder investor confidence and valuation. Additionally, the company's cash burn is at risk of increasing significantly as it accelerates pre-commercial activities, suggesting potential strain on financial resources without guaranteed revenue offsets. Furthermore, there are commercial risks associated with partnered assets, as demand could diminish or market share may shrink in response to evolving standards of care and the introduction of competitive therapies.

Curis (CRIS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Curis (CRIS) Forecast

Analysts have given Curis (CRIS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Curis (CRIS) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Curis (CRIS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.